UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000039429 |
|---|---|
| Receipt number | R000042687 |
| Scientific Title | Examination study of the effect that continuation intake of the lactic acid bacterium food for healthy adults gives to serum cholesterol for 12 weeks |
| Date of disclosure of the study information | 2021/05/22 |
| Last modified on | 2021/07/05 16:50:09 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Examination study of the effect that continuation intake of the lactic acid bacterium food for healthy adults gives to serum cholesterol for 12 weeks
Acronym
Examination study of the effect that continuation intake of the lactic acid bacterium food for healthy adults gives to serum cholesterol for 12 weeks
Scientific Title
Examination study of the effect that continuation intake of the lactic acid bacterium food for healthy adults gives to serum cholesterol for 12 weeks
Scientific Title:Acronym
Examination study of the effect that continuation intake of the lactic acid bacterium food for healthy adults gives to serum cholesterol for 12 weeks
Region
| Japan |
Condition
Condition
Healthy subjects
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The objective of this study is to investigate the effects on serum cholesterol by male and female who continue to taking test food for 12 weeks who are older 20 years old,aged less than 65 years old, and LDL-Cholesterol is less than 140mg/dL more than 120mg/dL.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
LDL-Cholesterol
Key secondary outcomes
Triglyceride
Total Cholesterol
HDL-Cholesterol
High sensitive CRP
Apolipoprotein A-I
Apolipoprotein B
oxidized LDL
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
12-weeks intake of the test food
Interventions/Control_2
12-weeks intake of the placebo food
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 65 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1)Japanese male and female aged 20 to 65 years old at the time of the informed consent.
2)Subject with LDL-Cholesterol>=120mg/dL and <140mg/dL.
3)Subject without a daily exercise habit.
4)Subject who has understood the purpose of the study, and agreed to participate it by signing the written informed consent.
Key exclusion criteria
1)Subject who smokes a lot.
2)Subject with the diarrheal disease chronically.
3)Subject who is taking medication or under medical treatment.
4)Subject who is under exercise therapy or dietetic therapy.
5)Subject who has an allergy for test food.
6)Subject who has or had a history of either medicine or alcohol dependence syndrome.
7)Subject who has or had a history of mental illness (depression) or sleep disturbance.
8)Subject who is on a night-shift or is a shift worker.
9)Subject whose lifestyle is extremely irregular.
10)Subject who has an unbalanced diet.
11)Subject with the bowel past surgical history,short bowel syndrome, pancreatitis, the existing illness of the biliary tract disease or history.
12)Subject with brain disease, a malignant tumor, immunologic disease, diabetes, hepatic disorder (hepatitis), renal disease, serious disease, thyroid disease, adrenal gland disease such as the heart disorder, and the like, the serious existing illness such as other metabolic disorders, and the like or the history.
13)Subject who uses a health food, a supplement affecting fat metabolism and medical supplies.
14)Subject who has participated in other clinical studies within the past 3 months from the day of the consent acquisition or who is planning to participate in other clinical studies during the current study.
15)Subject who has blood drawn 200mL within the past 1 months or 400mL within the past 3 months from the day of the consent acquisition.
16)Subject who is planning to get pregnant after the day of informed consent or is currently pregnant and lactating.
17)Subject who can't keep the daily records.
18)Subject who is judged as an inappropriate candidate according to the screening data.
19)Subject who is considered as an inappropriate candidate by the doctor in charge.
Target sample size
30
Research contact person
Name of lead principal investigator
| 1st name | Yo |
| Middle name | |
| Last name | Miyakoshi |
Organization
Kaneka Co., Ltd.
Division name
Pharma & Supplemental Nutrition Solutions Vehicle
Zip code
107-6028
Address
1-12-32 Akasaka Minato-ku Tokyo 107-6028 Japan
TEL
050-3133-9895
yo.miyakoshi@kaneka.co.jp
Public contact
Name of contact person
| 1st name | Daisuke |
| Middle name | |
| Last name | Ochitani |
Organization
HUMA R&D CORP
Division name
Clinical Development Division
Zip code
108-0014
Address
Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan
TEL
03-3431-1260
Homepage URL
ochitani@huma-rd.co.jp
Sponsor or person
Institute
HUMA R&D CORP
Institute
Department
Personal name
Funding Source
Organization
Kaneka Co., Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Ethics Committees of Nihonbashi Egawa Clinic
Address
2F Kotobuki Build. 1-1-3 Yaesu Chuo-ku, Tokyo 103-0028 Japan
Tel
03-5204-0311
jim@medipharma.co.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2021 | Year | 05 | Month | 22 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2019 | Year | 12 | Month | 25 | Day |
Date of IRB
| 2020 | Year | 01 | Month | 17 | Day |
Anticipated trial start date
| 2020 | Year | 02 | Month | 10 | Day |
Last follow-up date
| 2020 | Year | 05 | Month | 22 | Day |
Date of closure to data entry
| 2020 | Year | 06 | Month | 05 | Day |
Date trial data considered complete
| 2020 | Year | 06 | Month | 16 | Day |
Date analysis concluded
| 2020 | Year | 07 | Month | 17 | Day |
Other
Other related information
Management information
Registered date
| 2020 | Year | 02 | Month | 07 | Day |
Last modified on
| 2021 | Year | 07 | Month | 05 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042687
